A randomized controlled trial of antipsychotic combination in acute-phase schizophrenia

A randomized controlled trial of antipsychotic combination in acute-phase schizophrenia - A randomized controlled trial of antipsychotic combination in schizophrenia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003531

Enrollment

300

Registered

2010-05-31

Start date

2010-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

schizophrenia

Interventions

Early non-responder to risperidone(6mg or less) will be assigned to combination with olanzapine(20mg or less). Follow-up period is 8 weeks. Early non-responder to risperidone(6mg or less) will be ass

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: newly admitted as emergency cases, and met criteria of the DSM-IV for schizophrenia, schizophreniform disorder, or schizoaffective disorder

Exclusion criteria

Exclusion criteria: 1) obvious complications such as liver dysfunction, renal dysfunction, heart failure, and respiratory failure 2) diabetes mellitus 3) Patients who were pregnant or who want to become pregnant

Design outcomes

Primary

Measure	Time frame
50% and more improvement in the PANSS total score	—

Secondary

Measure	Time frame
PANSS, CGI, GAF treatment discontinuation	—

Countries

Japan

Contacts

Public ContactKotaro Hatta

Juntendo University Nerima Hospital Department of Psychiatry

khatta@juntendo.ac.jp03-5923-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026